Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Lyra Therapeutics ( (LYRA) ) is now available.
On August 20, 2025, Lyra Therapeutics received a Deficiency Letter from Nasdaq indicating that the company’s stockholders’ equity, reported at $1.6 million as of June 30, 2025, did not meet the minimum requirement of $2.5 million for continued listing on the Nasdaq Capital Market. Although this has no immediate effect on the trading of its stock, Lyra has until October 4, 2025, to submit a plan to regain compliance. The company is exploring various strategies to meet Nasdaq’s requirements, but there is no guarantee of acceptance or successful compliance, which could lead to potential delisting.
The most recent analyst rating on (LYRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.
Lyra Therapeutics’ overall stock score reflects significant financial struggles and weak technical indicators. However, recent corporate achievements and strategic plans offer some optimism for future growth, notably in the biotechnology sector’s volatile environment.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Lyra Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for patients with ear, nose, and throat diseases. The company is known for its innovative drug delivery systems aimed at improving patient outcomes in these specialized areas.
Average Trading Volume: 658,580
Technical Sentiment Signal: Sell
Current Market Cap: $11.66M
See more data about LYRA stock on TipRanks’ Stock Analysis page.